TriSalus Life SciencesTLSI
TLSI
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
23% more capital invested
Capital invested by funds: $10M [Q3] → $12.4M (+$2.35M) [Q4]
0.68% more ownership
Funds ownership: 7.41% [Q3] → 8.09% (+0.68%) [Q4]
9% less funds holding
Funds holding: 32 [Q3] → 29 (-3) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
82%
upside
Avg. target
$10.50
91%
upside
High target
$11
100%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street | 82%upside $10 | Buy Initiated | 13 Feb 2025 |
Roth MKM Jason Wittes 43% 1-year accuracy 9 / 21 met price target | 100%upside $11 | Buy Reiterated | 24 Jan 2025 |
Financial journalist opinion
Based on 5 articles about TLSI published over the past 30 days
Neutral
Seeking Alpha
11 hours ago
TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Operator Good morning, and welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
Neutral
Zacks Investment Research
15 hours ago
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago.
Neutral
Business Wire
17 hours ago
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full yea.
Neutral
Business Wire
1 day ago
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimb.
Neutral
Business Wire
3 weeks ago
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent publication, including the JVIR Editor's Award for Distinguished Laboratory Investigation and the J.
Neutral
Business Wire
1 month ago
TriSalus Life Sciences Announces Key Appointments to Board of Directors
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective a.
Neutral
Business Wire
1 month ago
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with OrbiMed, a healthcare investment firm. Pursuant to the to the Agreement, OrbiMed agree.
Neutral
Business Wire
2 months ago
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Full financial results for the year ended December 31, 2024 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $8.3 m.
Neutral
Business Wire
2 months ago
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode.
Positive
Seeking Alpha
3 months ago
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut
TriSalus Life Sciences continues to develop its TriNav infusion system, expanding its reach in liver and pancreatic cancer treatment, despite shifting focus from drug development. TLSI's financials show a $2.4 million net loss for the quarter, but management is optimistic about turning cash flow positive by 2025. The company faces risks with low cash reserves and potential need for dilutive fundraising, despite cost reduction efforts and growing product sales.
Charts implemented using Lightweight Charts™